Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Agios Pharmaceuticals, Inc. has 59.60M shares outstanding.

As of June 30, 2026, Agios Pharmaceuticals, Inc. maintains a current ratio of 10.22, meaning it holds 10.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Agios Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -34.34, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -31.89, reflecting losses generated across the asset base. The company generates approximately 3.26M in revenue per employee across its workforce of 527.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.26 indicates how many times Agios Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Agios Pharmaceuticals, Inc. recorded an income tax benefit of -17.75M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -7.20B and -7.19B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on July 27, 2026, Agios Pharmaceuticals, Inc.'s stock has gained approximately 0.00% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Agios Pharmaceuticals, Inc. generated 1.72B in revenue and converted that into -7.19B in net income, yielding earnings per share of -122.45. EBITDA reached -7.93B, while operating income came in at -8.02B.

As of June 30, 2026, Agios Pharmaceuticals, Inc. holds 10.79B in cash and equivalents against 544.61M in total debt, resulting in a net debt position of -1.74B. Total book value stands at 17.93B, with working capital of 11.31B providing operational flexibility.

Agios Pharmaceuticals, Inc. produced -6.30B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -81.35M in capital expenditures, free cash flow totaled -6.38B - equivalent to -108.74 per share.

Over the twelve months ended June 30, 2026, Agios Pharmaceuticals, Inc. posted a gross margin of 91.99, reflecting its pricing power and cost economics. The operating margin of -466.78 and net profit margin of -418.24 provide insight into operational efficiency.